Blog
RSS FeedPosted by Michael Wonder on 19 Jul 2019
PBAC Public Summary Documents (first time rejections and deferrals) - March 2019 meeting
19 July 2019 - The Public Summary Documents (first time rejections and deferrals) from the March 2019 PBAC meeting are now ...
Posted by Michael Wonder on 18 Jul 2019
Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment
16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...
Posted by Michael Wonder on 17 Jul 2019
Breast cancer patients to have further NICE approved drug combination option on Cancer Drugs Fund
17 July 2019 - Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on ...
Posted by Michael Wonder on 15 Jul 2019
Implementation of “coverage with evidence development” drug approval strategies found lacking
15 July 2019 - Lessons from early deployments in The Netherlands. ...
Posted by Michael Wonder on 15 Jul 2019
NICE recommends Skyrizi, Forxiga
15 July 2019 - NICE has recommended two new drugs on the NHS, AbbVie’s Skyrizi (risankizumab) and AstraZeneca’s Forxiga (dapagliflozin) ...
Posted by Michael Wonder on 13 Jul 2019
Early benefit assessment reveals weaknesses in the development of new drugs
11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...
Posted by Michael Wonder on 12 Jul 2019
Aimmune statement on ICER final report on AR101 for peanut allergy
11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...
Posted by Michael Wonder on 12 Jul 2019
NICE recommends innovative treatment for type 1 diabetes
12 July 2019 - It’s estimated that around 90,000 people could be eligible for treatment with dapagliflozin. ...
Posted by Michael Wonder on 11 Jul 2019
ICER publishes evidence report on treatments for Duchenne muscular dystrophy
11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...
Posted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...
Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...
Posted by Michael Wonder on 09 Jul 2019
Institute for Clinical and Economic Review lists potential topics for assessments in 2020
9 July 2019 - The Institute for Clinical and Economic Review has released its preliminary list of potential assessment topics ...
Posted by Michael Wonder on 09 Jul 2019
NICE Onpattro approval puts Alnylam back in hATTR running
9 July 2019 - NICE has recommended the use of Alynylam’s Onpattro (patisiran), after issuing a preliminary ‘no’, back in ...
Posted by Michael Wonder on 08 Jul 2019
New treatment approved for patients with breast cancer in Scotland
8 July 2019 - A new drug for patients with advanced breast cancer has been approved for use by the ...
Posted by Michael Wonder on 08 Jul 2019
SMC - July 2019 decisions
8 July 2019 - A medicine used to treat advanced breast cancer has today been accepted by the Scottish Medicines ...